Coronavirus Company News Summary – NRx Pharmaceuticals and IIBR Collaborate on the Development of a Covid-19 Vaccine
NRx Pharmaceuticals, a clinical-stage pharmaceutical company, has signed a memorandum of understanding with the government of Israel to authorize the exclusive global development, manufacture and commercialization of the Covid-19 vaccine developed by the Israel Institute of Biological Research (IIBR) . The BriLife vaccine is based on a previous vaccine platform, approved by the United States Food and Drug Administration, which has been optimized by the IIBR. The vaccine should initially be given by traditional injection.
Moderna has reached an agreement with the Argentine government to provide 20 million doses of Moderna’s Covid-19 vaccine or its updated booster variant, if allowed. Delivery of doses is expected to begin in the first quarter of 2022. The company said it continues to commit to making its Covid-19 vaccines available to the world as it seeks to end the pandemic through efforts to vaccination.
BioNTech announced that Fosun Industrial, a 100% subsidiary of its partner Shanghai Fosun Pharmaceutical, has entered into advance supply agreements to supply its mRNA-based Covid-19 vaccine with Taiwan Semiconductor Manufacturing Co., Hon Hai, the Yonglin Charitable Foundation and Zuellig Pharma, respectively. Fosun Industrial will sell a total of 10 million doses of vaccine to Zuellig Pharma. These Covid-19 mRNA vaccines will support local vaccination after being donated to the relevant disease control agency in Taiwan.